Rallybio Corp (Nasdaq:RLYB)

Health Care/Life Sciences • Pharmaceuticals

CIK 1739410

Company

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Address
234 Church Street
Suite 1020
New Haven, Connecticut 06510

Employees
41

Stock Info

Close
$1.8550

Day Range
1.8400 - 2.1599

52 Week Range
1.2250 - 9.1400

Average volume
236.74K

Short Interest
1.08M (02/15/24)

% of Float Shorted
6.26%

Market Cap
$74.45M

Revenue
N/A

Net Income
-$66.65M

2020 Sales Growth
N/A

Rev. per Employee
N/A

P/E Ratio
N/A

EPS
-$1.8014

Yield
N/A

Dividend
N/A

Ex-Dividend Date
N/A

Key Executives

Board Of Directors

Executive Chairman
Martin W MacKay PhD

President, Chief Executive Officer & Director
Stephen Uden MD

Director
Christine A Nash MBA

Director
Liu Hui PhD, MBA

Director
Wendy K Chung MD, PhD

Independent Director
Helen Marie Boudreau MBA

Independent Director
Robert L Hopfner PhD, MBA

Independent Director
Ronald M Hunt MBA

Independent Director
Lucian Iancovici MD

Independent Director
Kush M Parmar MD, PhD

Independent Director
Paula Soteropoulos

SEC filings

Date	Form	Event
8 Aug, 2024	8-K
8 Aug, 2024	10-Q
30 Jul, 2024	SC 13G/A
30 Jul, 2024	SC 13G
23 Jul, 2024	8-K
21 May, 2024	8-K
20 May, 2024	EFFECT
17 May, 2024	4
17 May, 2024	4
17 May, 2024	4
17 May, 2024	4
17 May, 2024	4
17 May, 2024	4
17 May, 2024	4
17 May, 2024	4
16 May, 2024	CORRESP
16 May, 2024	UPLOAD
10 May, 2024	S-3
9 May, 2024	8-K
9 May, 2024	10-Q
22 Apr, 2024	D
11 Apr, 2024	DEF 14A
10 Apr, 2024	8-K
13 Mar, 2024	S-8
12 Mar, 2024	8-K
12 Mar, 2024	10-K
16 Feb, 2024	4
16 Feb, 2024	4
16 Feb, 2024	4
16 Feb, 2024	4
14 Feb, 2024	SC 13G/A
12 Feb, 2024	SC 13D/A
9 Feb, 2024	SC 13G/A
6 Feb, 2024	8-K
4 Jan, 2024	4
4 Jan, 2024	4
2 Jan, 2024	SC 13G/A
20 Dec, 2023	8-K
9 Nov, 2023	10-Q
9 Nov, 2023	8-K
8 Aug, 2023	10-Q
8 Aug, 2023	8-K
29 Jun, 2023	8-K	CEO Change
22 May, 2023	8-K
19 May, 2023	4
19 May, 2023	4
19 May, 2023	4
19 May, 2023	4
19 May, 2023	4
19 May, 2023	4
19 May, 2023	4
19 May, 2023	4
12 May, 2023	424B3
12 May, 2023	EFFECT
11 May, 2023	CORRESP
11 May, 2023	UPLOAD
10 May, 2023	S-8
9 May, 2023	S-3
9 May, 2023	10-Q
9 May, 2023	8-K
10 Apr, 2023	DEF 14A
16 Mar, 2023	4
9 Mar, 2023	4
9 Mar, 2023	4
6 Mar, 2023	8-K
6 Mar, 2023	10-K
9 Feb, 2023	SC 13G/A
6 Feb, 2023	4
6 Feb, 2023	4
6 Feb, 2023	SC 13G/A
6 Feb, 2023	4
1 Feb, 2023	3
1 Feb, 2023	4
1 Feb, 2023	SC 13G/A
31 Jan, 2023	8-K
23 Jan, 2023	SC 13G/A
5 Jan, 2023	4
5 Jan, 2023	4
5 Jan, 2023	4
5 Jan, 2023	4
1 Dec, 2022	8-K
17 Nov, 2022	SC 13G
17 Nov, 2022	4
14 Nov, 2022	8-K
14 Nov, 2022	424B5
10 Nov, 2022	424B5
7 Nov, 2022	10-Q
7 Nov, 2022	8-K
28 Sep, 2022	8-K
15 Aug, 2022	424B5
15 Aug, 2022	EFFECT
11 Aug, 2022	UPLOAD
11 Aug, 2022	CORRESP
8 Aug, 2022	8-K
8 Aug, 2022	10-Q
8 Aug, 2022	S-3
3 Aug, 2022	4
3 Aug, 2022	3
2 Aug, 2022	8-K
7 Jun, 2022	4
7 Jun, 2022	4
7 Jun, 2022	SC 13D/A
6 Jun, 2022	S-8
2 Jun, 2022	8-K
27 May, 2022	8-K
26 May, 2022	4
26 May, 2022	4
26 May, 2022	4
26 May, 2022	4
26 May, 2022	4
26 May, 2022	4
26 May, 2022	4
25 May, 2022	4
25 May, 2022	4
10 May, 2022	10-Q
10 May, 2022	8-K
25 Apr, 2022	DEF 14A
6 Apr, 2022	3
6 Apr, 2022	4
6 Apr, 2022	4
6 Apr, 2022	3
4 Apr, 2022	8-K
23 Mar, 2022	4
15 Mar, 2022	10-K
15 Mar, 2022	8-K
7 Mar, 2022	8-K
14 Feb, 2022	SC 13G/A
11 Feb, 2022	SC 13G
10 Feb, 2022	4
10 Feb, 2022	4
9 Feb, 2022	4
9 Feb, 2022	4
9 Feb, 2022	4
9 Feb, 2022	4
8 Feb, 2022	SC 13G
21 Jan, 2022	4
21 Jan, 2022	SC 13G
18 Jan, 2022	SC 13D/A
14 Jan, 2022	4
12 Jan, 2022	4
11 Jan, 2022	4
5 Jan, 2022	4
5 Jan, 2022	4
5 Jan, 2022	4
5 Jan, 2022	4
5 Jan, 2022	4
10 Nov, 2021	8-K
10 Nov, 2021	10-Q
9 Sep, 2021	10-Q
9 Sep, 2021	8-K
12 Aug, 2021	SC 13D
12 Aug, 2021	SC 13D
12 Aug, 2021	SC 13D
9 Aug, 2021	SC 13G
4 Aug, 2021	3/A
4 Aug, 2021	SC 13G
4 Aug, 2021	4
4 Aug, 2021	4
4 Aug, 2021	4
4 Aug, 2021	4
4 Aug, 2021	4
4 Aug, 2021	4
2 Aug, 2021	S-8
2 Aug, 2021	4
2 Aug, 2021	8-K
30 Jul, 2021	424B4	IPO completed
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	CERT
29 Jul, 2021	8-A12B
28 Jul, 2021	EFFECT
28 Jul, 2021	SEC STAFF
28 Jul, 2021	S-1MEF
26 Jul, 2021	CORRESP
26 Jul, 2021	CORRESP
22 Jul, 2021	S-1/A
12 Jul, 2021	CORRESP
2 Jul, 2021	S-1
7 Jun, 2021	DRSLTR
7 Jun, 2021	DRS/A
24 May, 2021	UPLOAD
13 May, 2021	SEC STAFF
27 Apr, 2021	DRS

Last update:2024-03-06 13:23:36.272590

Sign Up to Subscribe

Interested in special situations?

Join Tickerverse

customize event filters
create watchlists, bookmarks
get email notifications for the latest special situations
browse and analyze public companies, executives and SEC filings

Tickerverse is a great way to find investment opportunities in corporate actions.

By signing up you agree to our Terms of Service and Privacy Policy.